TRIQUILAR 28 TABLET

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

LEVONORGESTREL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL; ETHINYL ESTRADIOL; LEVONORGESTREL

Beszerezhető a:

BAYER INC

ATC-kód:

G03AB03

INN (nemzetközi neve):

LEVONORGESTREL AND ESTROGEN

Adagolás:

125MCG; 30MCG; 40MCG; 50MCG; 30MCG; 75MCG

Gyógyszerészeti forma:

TABLET

Összetétel:

LEVONORGESTREL 125MCG; ETHINYL ESTRADIOL 30MCG; ETHINYL ESTRADIOL 40MCG; LEVONORGESTREL 50MCG; ETHINYL ESTRADIOL 30MCG; LEVONORGESTREL 75MCG

Az alkalmazás módja:

ORAL

db csomag:

28

Recept típusa:

Prescription

Terápiás terület:

CONTRACEPTIVES

Termék összefoglaló:

Active ingredient group (AIG) number: 0618648001; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2007-03-08

Termékjellemzők

_TRIQUILAR Product Monograph _
_Page 1 of 54_
PRODUCT MONOGRAPH
PR
TRIQUILAR
® 21
PR
TRIQUILAR
® 28
0.05 mg levonorgestrel and 0.03 mg ethinyl estradiol tablets
0.075 mg levonorgestrel and 0.04 mg ethinyl estradiol tablets
0.125 mg levonorgestrel and 0.03 mg ethinyl estradiol tablets
USP
Oral Contraceptive
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Date of Revision:
May 26, 2017
Submission Control No: 202824
© 2017, Bayer Inc.
® TM see www.bayer.ca/tm-mc
_TRIQUILAR Product Monograph _
_Page 2 of 54_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND ADMINISTRATION
..............................................................................23
OVERDOSAGE
................................................................................................................26
ACTION AND CLINICAL PHARMACOLOGY
............................................................27
STORAGE AND STABILITY
..........................................................................................30
SPECIAL HANDLING INSTRUCTIONS
.......................................................................30
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
.....................................